Bluebird Bio is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include our LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy. Bluebird Bio programs in oncology are built upon its leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor and T cell receptor  T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. The Company also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across its pipeline.

Type
Public
HQ
Cambridge, US
Founded
1992
Size (employees)
418 (est)+24%
Bluebird Bio was founded in 1992 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Bluebird Bio

Nick Leschly

Nick Leschly

CEO
Jeffrey Walsh

Jeffrey Walsh

Chief Operating Officer

Bluebird Bio Office Locations

Bluebird Bio has offices in Cambridge and Seattle
Cambridge, US (HQ)
60 Binney St.
Seattle, US
208 1616 Eastlake Ave E
Show all (2)
Report incorrect company information

Bluebird Bio Financials and Metrics

Bluebird Bio Financials

Bluebird Bio's revenue was reported to be $35.43 m in FY, 2017
USD

Revenue (FY, 2017)

35.4 m

Net income (FY, 2017)

(335.6 m)

EBIT (FY, 2017)

(332.2 m)

Market capitalization (18-Apr-2018)

7.6 b

Cash (31-Dec-2017)

758.5 m
Bluebird Bio's current market capitalization is $7.6 b.
Annual
USDFY, 2013Y, 2014Y, 2015FY, 2016FY, 2017

Revenue

20.2 m25.4 m14.1 m6.2 m35.4 m

Revenue growth, %

26%(45%)(56%)

General and administrative expense

65.1 m93.6 m

R&D expense

204.8 m273 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

6.4 m6.3 m6.3 m6.4 m6.3 m4.9 m1.3 m1.5 m1.6 m1.6 m6.8 m16.7 m7.7 m

General and administrative expense

3.8 m5.5 m5.7 m6.6 m7.3 m10.7 m13.7 m16 m18.4 m14.6 m20.3 m21.2 m23 m

R&D expense

8.7 m11.5 m13.9 m16.6 m23.7 m44.3 m30.4 m41.9 m41.8 m64 m55 m64.3 m61.5 m

Operating expense total

12.5 m17 m19.7 m23.4 m31.3 m57 m44.5 m58.9 m61.5 m79.7 m76.7 m84.5 m85.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

206.3 m347.8 m164.3 m278.9 m758.5 m

Accounts Receivable

Inventories

5 m4.5 m6 m19.8 m

Current Assets

212 m480 m524 m724.2 m1.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

216.8 m192.5 m175.7 m89.6 m133.2 m593.3 m417.5 m192.6 m222.6 m245.2 m216 m686.3 m238 m

Current Assets

221.5 m195.9 m182.9 m223.3 m340.8 m815.5 m713.2 m561 m582.9 m608.8 m667.3 m1.1 b758.7 m

PP&E

5.4 m12 m12.9 m15 m16.9 m16.8 m61.6 m96.6 m109.3 m131.7 m181.7 m180.4 m182.4 m

Goodwill

13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(25.3 m)(48.7 m)(166.8 m)(263.5 m)(335.6 m)

Depreciation and Amortization

941 k4.2 m7.4 m9.6 m13.5 m

Inventories

(14 m)

Accounts Payable

2.1 m(2.2 m)2.5 m6.7 m526 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(17.2 m)(10.6 m)(1.5 m)(17 m)(24.8 m)(51.8 m)(42.9 m)(56.3 m)(58.8 m)(77 m)(68.7 m)

Depreciation and Amortization

610 k

Accounts Payable

(1 m)2.6 m3.6 m2.6 m2.3 m3.5 m3.1 m2.4 m6.7 m8.8 m

Cash From Operating Activities

48.9 m
USDY, 2017

Revenue/Employee

98 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information